Epithelial-to-mesenchymal transition (EMT) and small cell lung cancer (SCLC) or squamous cell carcinoma conversion have been reported after ALK inhibitor therapy for ALK-p adenocarcinoma [83,84,85,86]. The gene discussed is ALK; the disease is adenocarcinoma.